COMPASS THERAPEUTICS, INC. Operating Income
COMPASS THERAPEUTICS, INC. (CMPX) reported Operating Income of -$26.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$26.98M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$20.30M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$17.99M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$15.82M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$72.84M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$56.63M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$50.36M.
- COMPASS THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$41.66M.
| Period end | Operating Income (Loss) 0 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$26.98M 10-Q · filed 2026-08-06 | -$47.28M 10-Q · filed 2026-08-06 | -$65.27M derived: sum of 3 quarters · filed 2026-08-06 | -$81.08M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$20.30M 10-Q · filed 2026-05-05 | -$38.29M derived: sum of 2 quarters · filed 2026-05-05 | -$54.11M derived: sum of 3 quarters · filed 2026-05-05 | -$75.17M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$17.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$33.81M derived: sum of 2 quarters · filed 2026-03-05 | -$54.87M derived: sum of 3 quarters · filed 2026-08-06 | -$72.84M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$15.82M 10-Q · filed 2025-11-05 | -$36.88M derived: sum of 2 quarters · filed 2026-08-06 | -$54.85M 10-Q · filed 2025-11-05 | -$71.42M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$21.07M 10-Q · filed 2026-08-06 | -$39.03M 10-Q · filed 2026-08-06 | -$55.61M derived: sum of 3 quarters · filed 2026-08-06 | -$67.84M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$17.97M 10-Q · filed 2026-05-05 | -$34.54M derived: sum of 2 quarters · filed 2026-05-05 | -$46.78M derived: sum of 3 quarters · filed 2026-05-05 | -$61.82M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | -$16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$28.81M derived: sum of 2 quarters · filed 2026-03-05 | -$43.86M derived: sum of 3 quarters · filed 2026-03-05 | -$56.63M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$12.24M 10-Q · filed 2025-11-05 | -$27.28M derived: sum of 2 quarters · filed 2025-11-05 | -$40.05M 10-Q · filed 2025-11-05 | -$55.45M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | -$15.04M 10-Q · filed 2025-08-11 | -$27.81M 10-Q · filed 2025-08-11 | -$43.21M derived: sum of 3 quarters · filed 2025-08-11 | -$55.13M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | -$12.77M 10-Q · filed 2025-05-08 | -$28.16M derived: sum of 2 quarters · filed 2025-05-08 | -$40.09M derived: sum of 3 quarters · filed 2025-05-08 | -$53.43M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$15.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$27.32M derived: sum of 2 quarters · filed 2025-02-27 | -$40.66M derived: sum of 3 quarters · filed 2025-02-27 | -$50.36M 10-K · filed 2025-02-27 | ||
| 2023-09-30 | -$11.93M 10-Q · filed 2024-11-12 | -$25.26M derived: sum of 2 quarters · filed 2024-11-12 | -$34.97M 10-Q · filed 2024-11-12 | -$47.86M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$13.34M 10-Q · filed 2024-08-12 | -$23.05M 10-Q · filed 2024-08-12 | -$35.94M derived: sum of 3 quarters · filed 2024-08-12 | -$48.53M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | -$9.71M 10-Q · filed 2024-05-13 | -$22.60M derived: sum of 2 quarters · filed 2024-05-13 | -$35.20M derived: sum of 3 quarters · filed 2024-05-13 | -$44.18M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$12.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$25.49M derived: sum of 2 quarters · filed 2024-03-21 | -$34.47M derived: sum of 3 quarters · filed 2024-03-21 | -$41.66M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | -$12.60M 10-Q · filed 2023-11-09 | -$21.59M derived: sum of 2 quarters · filed 2023-11-09 | -$28.77M 10-Q · filed 2023-11-09 | -$41.77M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$8.99M 10-Q · filed 2023-08-03 | -$16.17M 10-Q · filed 2023-08-03 | -$29.17M derived: sum of 3 quarters · filed 2023-08-03 | -$35.02M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | -$7.18M 10-Q · filed 2023-05-04 | -$20.18M derived: sum of 2 quarters · filed 2023-05-04 | -$26.04M derived: sum of 3 quarters · filed 2023-05-04 | -$81.73M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | -$13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$18.86M derived: sum of 2 quarters · filed 2023-03-15 | -$74.54M derived: sum of 3 quarters · filed 2023-03-15 | -$81.88M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | -$5.85M 10-Q · filed 2022-11-09 | -$61.54M derived: sum of 2 quarters · filed 2022-11-09 | -$68.88M 10-Q · filed 2022-11-09 | -$76.83M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$55.69M 10-Q · filed 2022-08-01 | -$63.02M 10-Q · filed 2022-08-01 | -$70.98M derived: sum of 3 quarters · filed 2022-08-01 | -$79.94M derived: sum of 4 quarters · filed 2022-08-01 | ||
| 2021-03-31 | -$7.34M 10-Q · filed 2022-05-09 | -$15.29M derived: sum of 2 quarters · filed 2022-05-09 | -$24.25M derived: sum of 3 quarters · filed 2022-05-09 | -$29.32M derived: sum of 4 quarters · filed 2022-05-09 | ||
| 2020-12-31 | -$7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$16.91M derived: sum of 2 quarters · filed 2022-03-18 | -$21.98M derived: sum of 3 quarters · filed 2022-03-18 | -$27.81M 10-K · filed 2022-03-18 | ||
| 2020-09-30 | -$8.96M 10-Q · filed 2021-11-12 | -$14.03M derived: sum of 2 quarters · filed 2021-11-12 | -$19.86M 10-Q · filed 2021-11-12 | -$19.87M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | -$5.07M 10-Q · filed 2021-08-16 | -$10.90M 10-Q · filed 2021-08-16 | -$10.91M derived: sum of 3 quarters · filed 2021-08-16 | -$19.29M derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2020-03-31 | -$5.83M 10-Q · filed 2021-04-30 | -$5.84M derived: sum of 2 quarters · filed 2021-04-30 | -$14.22M derived: sum of 3 quarters · filed 2021-04-30 | -$32.10K 10-K · filed 2020-06-08 | ||
| 2019-12-31 | -$10.24K 10-Q · filed 2020-02-14 | -$8.39M derived: sum of 2 quarters · filed 2020-11-09 | -$27.71K 10-Q · filed 2020-02-14 | -$34.05M 10-K · filed 2021-03-05 | ||
| 2019-09-30 | -$8.38M 10-Q · filed 2020-11-09 | -$7.15K 10-Q · filed 2019-11-13 | -$17.47K 10-Q · filed 2019-11-13 | -$27.65M 10-Q · filed 2020-11-09 | -$17.07M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$8.67M 10-Q · filed 2020-08-13 | -$10.32K 10-Q · filed 2019-08-13 | -$19.27M 10-Q · filed 2020-08-13 | -$8.69M derived: sum of 3 quarters · filed 2020-08-13 | -$8.70M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | -$7.81K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08 | -$17.08K derived: sum of 2 quarters · filed 2020-06-08 | -$24.86K derived: sum of 3 quarters · filed 2020-06-08 | -$32.76K 10-K · filed 2020-06-08 | ||
| 2018-12-31 | -$9.27K 10-Q · filed 2020-02-14 | -$17.05K derived: sum of 2 quarters · filed 2020-02-14 | -$24.95K 10-Q · filed 2020-02-14 | |||
| 2018-09-30 | -$7.79K 10-Q · filed 2019-11-13 | -$15.68K 10-Q · filed 2019-11-13 | ||||
| 2018-06-30 | -$7.89K 10-Q · filed 2019-08-13 | |||||
| 2018-03-31 | -$35.00K 10-K · filed 2019-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |